A team of researchers from VHIR has presented the results of a wide epidemiological study to evaluate the risk of the suspension of antiaggregant treatments during the first year after the placement of a liberating pharmaco-active stent. The results of the study have been published today in the magazine JACC and have deserved an editorial in the same publication. The study indicates that the suspension of these treatments during the first year after the placement of the stent does not seem to increase the risk of appearance of cardiac major problems if the interruption is temporary, during a short period of approximately 7 days of duration, in a controlled way and after the first month after the implantation of the stent.